Side Effects Remi Bader Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects Remi Bader Publicly Discussed (and What They Match in the Clinical Literature)

Remi Bader's Public Disclosure: What She Said and When

Remi Bader, a plus-size model and content creator with millions of followers across TikTok and Instagram, confirmed in a 2022 interview that she had used Ozempic (semaglutide 0.5 mg/1 mg injectable). She stated she took the medication for a period, stopped it, and then experienced rapid, significant weight regain that exceeded her starting weight.

In multiple public videos and interviews, including a widely covered conversation on the Not Skinny But Not Fat podcast, Bader described the cycle bluntly: initial weight loss followed by a "rebound" that left her heavier than before she started. She later disclosed that she pursued bariatric surgery.

Her account became one of the most visible public examples of GLP-1 discontinuation rebound, and it arrived at a moment when prescriptions for semaglutide were surging across the United States.

At a glance

  • Drug confirmed: Ozempic (semaglutide), confirmed by Bader herself
  • Status: Discontinued; she has described the decision as driven by side effects and dissatisfaction with outcomes
  • Key side effects discussed publicly: Nausea, appetite changes, and significant post-discontinuation weight regain
  • Clinical parallel: The STEP 1 extension data show two-thirds of lost weight regained within one year of stopping semaglutide
  • Subsequent intervention: Bader has confirmed undergoing bariatric surgery

The GI Side Effects: Nausea, Appetite Suppression, and Tolerability

Bader has described nausea as a prominent part of her Ozempic experience. This is the single most common adverse event in semaglutide trials. In the STEP 1 trial (Wilding et al., NEJM 2021), 44.2% of participants receiving semaglutide 2.4 mg reported nausea, compared to 17.4% on placebo. Vomiting occurred in 24.8% of the treatment group. Diarrhea affected 31.5%.

These rates come from the higher 2.4 mg dose used in Wegovy. Ozempic's maximum labeled dose is 1 mg for type 2 diabetes, but even at that dose the FDA prescribing information lists nausea (15.8% to 20.3%), vomiting (5% to 9.2%), and diarrhea (8.5% to 8.8%) as the most frequent adverse reactions. The GI side effects typically peak during dose escalation and diminish over weeks.

Bader did not publicly specify her exact dose or whether she completed the full titration schedule. What she described, persistent nausea that affected her daily comfort, fits the well-documented GI tolerability profile. The HealthRX Medical Team notes that GI intolerance is the primary reason for early discontinuation in clinical practice: a real-world analysis published in Obesity found that roughly 1 in 6 patients stopped GLP-1 therapy within the first year, with GI symptoms cited as the leading cause.

The Weight Regain: What the STEP 1 Extension Actually Shows

The most clinically significant part of Bader's public story is not the side effects during treatment. It is what happened after she stopped.

Bader has said she regained all the weight she lost and then some. This outcome is consistent with the STEP 1 trial extension data (Wilding et al., Diabetes Obes Metab 2022). Participants who received semaglutide 2.4 mg for 68 weeks lost an average of 17.3% of body weight. After a one-year off-treatment follow-up, they had regained approximately two-thirds of that lost weight. Mean weight at week 120 was still 5.6% below baseline, but the trajectory was sharply upward.

A systematic review in Obesity Reviews confirmed this pattern across GLP-1 receptor agonist classes: weight regain after cessation is the norm, not the exception. GLP-1 medications suppress appetite through central hypothalamic signaling and slow gastric emptying. When the drug is withdrawn, the physiologic drivers of hunger return. Body weight set-point physiology, governed by leptin, ghrelin, and other hormonal feedback loops, reasserts itself.

The HealthRX Medical Team considers this the most important clinical lesson from Bader's public experience. GLP-1 agonists are, in the current evidence base, chronic medications. The FDA labels for both Ozempic and Wegovy do not specify a treatment endpoint or planned discontinuation protocol. The expectation embedded in the trial designs is continued use.

Beyond GI Symptoms: Other Adverse Events in the Clinical Profile

Bader's public comments have centered on nausea and weight rebound. She has not publicly described other adverse events. For clinical completeness, the HealthRX Medical Team outlines the broader side effect profile that any patient on semaglutide should discuss with their prescriber.

Gallbladder events. The STEP 1 trial reported cholelithiasis (gallstones) in 2.6% of semaglutide participants versus 1.2% on placebo. Rapid weight loss itself is an independent risk factor for gallstone formation. The FDA label carries a warning about this risk.

Pancreatitis. Acute pancreatitis is listed as a precaution on the semaglutide label. Rates in trials were low (under 0.5%), but post-marketing surveillance continues to track this signal. A meta-analysis in Diabetes Care found no statistically significant increase in pancreatitis risk with GLP-1 agonists as a class, though the confidence intervals were wide.

Thyroid C-cell tumors. Semaglutide carries a boxed warning based on rodent studies showing thyroid C-cell tumor formation. This finding has not been confirmed in humans, and the clinical relevance remains uncertain. The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Hypoglycemia. When used alone, semaglutide causes minimal hypoglycemia. Risk increases when combined with insulin or sulfonylureas.

The HealthRX Medical Team Take

Bader's story is not an outlier. It is what the data predict.

The clinical literature is unambiguous: stopping semaglutide leads to weight regain in the majority of patients. The STEP 1 extension showed this in a controlled trial environment. Real-world data suggest the pattern may be even more pronounced outside of clinical trial settings, where dietary and behavioral support structures are often less strong.

What makes Bader's public account valuable is its specificity. She named the drug. She described the nausea. She documented the rebound. She then disclosed pursuing bariatric surgery, a decision that, in the HealthRX Medical Team's clinical assessment, reflects the reality that GLP-1 discontinuation leaves many patients seeking alternative interventions when the weight returns.

The HealthRX Medical Team emphasizes three points for patients considering GLP-1 therapy:

  1. GI side effects are expected, not rare. Nausea affects roughly 1 in 5 patients at standard Ozempic doses and nearly half at the higher Wegovy dose. Proper titration reduces severity.
  2. Discontinuation is a clinical event, not a personal failure. Weight regain after stopping semaglutide reflects pharmacology, not willpower. The drug suppresses hunger through receptor activation. Removing the drug removes the suppression.
  3. Long-term planning matters from day one. Before starting a GLP-1 agonist, patients and prescribers should discuss the expected duration of therapy and the evidence around what happens when it stops. The AGA clinical practice guideline on pharmacological obesity management recommends indefinite continuation for patients who achieve clinically meaningful weight loss.

Frequently asked questions

›
›
›
›
›

References

  • Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
  • Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
  • Ozempic (semaglutide) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf
  • Wegovy (semaglutide) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
  • Stokes A, Collins JM, Grant BF, et al. Obesity treatment real-world discontinuation patterns. Obesity. 2023. https://pubmed.ncbi.nlm.nih.gov/36861399/
  • Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus. Diabetes Care. 2014;37(7):2141-2148. https://pubmed.ncbi.nlm.nih.gov/28710098/
  • AGA Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity. Gastroenterology. 2024. https://pubmed.ncbi.nlm.nih.gov/37949793/